Biotech IV Monitor

ZLAB — Zai Lab Limited

$2.2B market cap · 4 upcoming readouts tracked

Clinical trial readout dates for Zai Lab Limited, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is March 2027.

Next readoutMarch 2027in ~4 months
Upcoming readouts43 Phase 3
Market cap$2.2B
Cash & investments$560M~12 quarters at last loss rate
Recent 8-K filings2latest 2026-11-05

Upcoming readouts

Phase 3 ZL-1109 (VRDN-003)
Thyroid Eye Disease (TED) · NCT07211776
March 2027
Ongoing
Phase 1/2 ZL-1310
Solid Tumors · NCT06885281
August 2027
Recruiting
Phase 3 ZL-1310
Small-cell Lung Cancer · NCT07218146
June 2028
Recruiting
Phase 3 ZL-1310 in combination with Atezolizumab or Durvalumab
Extensive-Stage Small Cell Lung Cancer · NCT07796100
June 2030
Not Yet Recruiting

Cash position

Zai Lab Limited reported $560M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). Its net loss for that quarter was $46M; at that rate the cash would last about 12 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-05
8-K Other Events — often topline trial data2026-10-23

Companies working on similar indications

Discussion

No messages yet. If you follow ZLAB, you can start the conversation.
Track ZLAB in real time
See live implied volatility for ZLAB and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on ZLAB
Contact — questions or corrections about ZLAB: dukeupt@gmail.com